Clinical Trials Sponsored by Xuanzhu Biopharmaceutical Co., Ltd.

Total 396 results

Xuanzhu Biopharmaceutical Co., Ltd.

Not yet recruiting

A Study of XZB-0004 in Patients With Solid Tumors

NSCLC | Advanced Solid Tumor

China
Xuanzhu Biopharmaceutical Co., Ltd.

Not yet recruiting

A Study of KM602 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Xuanzhu Biopharmaceutical Co., Ltd.

Not yet recruiting

To Evaluate the Phase I Clinical Study of XZB-0004 in Patients With AML and MDS

AML | MDS

China
Xuanzhu Biopharmaceutical Co., Ltd.

Not yet recruiting

A Clinical Trial of XZP-3287 for Material Balance

Healthy Male Subjects

China
Xuanzhu Biopharmaceutical Co., Ltd.

Recruiting

A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumors | Locally Advanced or Metastatic Non-small Cell Lung Cancer

China
Xuanzhu Biopharmaceutical Co., Ltd.

Recruiting

Effect of Clarithromycin and Rifampicin on the Pharmacokinetics of XZP-3287 in Healthy Subjects

Healthy

China
Xuanzhu Biopharmaceutical Co., Ltd.

Recruiting

A Phase I Clinical Trial of XZP-5610 Tablets in Healthy Subjects

Nonalcoholic Steatohepatitis (NASH)

China
Xuanzhu Biopharmaceutical Co., Ltd.

Not yet recruiting

A Study of KM501 in Patients With Solid Tumors

Advanced Solid Tumors

China
Xuanzhu Biopharmaceutical Co., Ltd.

Not yet recruiting

A Study of Anaprazole Sodium Enteric-coated Tablets in the Treatment of Reflux Esophagitis

Gastrointestinal Diseases | Gastroesophageal Reflux | Esophageal Motility Disorders | Deglutition Disorders | Esophageal Diseases | Esophagitis | Reflux Esophagitis

China
Xuanzhu Biopharmaceutical Co., Ltd.

Not yet recruiting

Drug-drug Interaction Study of XZP-3621 Tablet

Healthy Subjects

China
Xuanzhu Biopharmaceutical Co., Ltd.

Recruiting

A Phase I Study of XZP-3621 in Chinese Patients With ALK or ROS1 Rearrangement Non-small Cell Lung Cancer

ROS1 Rearrangement Non-small Cell Lung Cancer | ALK Rearrangement Non-small Cell Lung Cancer

China
Xuanzhu Biopharmaceutical Co., Ltd.

Not yet recruiting

A Study of the Absorption, Metabolism and Excretion of [14C]XZP-3621 in Human

Healthy Volunteers

China
Xuanzhu Biopharmaceutical Co., Ltd.

Not yet recruiting

A Study of XZP-3621 in Chinese Patients With ALK Positive NSCLC

ALK-positive NSCLC

China
Xuanzhu Biopharmaceutical Co., Ltd.

Not yet recruiting

A Study of KM257 in Patients With Advanced HER2-positive or Expressing Solid Tumors.

Advanced Solid Tumor

China
Xuanzhu Biopharmaceutical Co., Ltd.

Not yet recruiting

A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer

Advanced Breast Cancer

China
Xuanzhu Biopharmaceutical Co., Ltd.

Not yet recruiting

A Study to Evaluate and Compare the Efficacy and Safety of XZP-3621 Versus Crizotinib

Non-small Cell Lung Cancer

China
Xuanzhu Biopharmaceutical Co., Ltd.

Recruiting

A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer

Advanced Breast Cancer

China
Xuanzhu Biopharmaceutical Co., Ltd.

Not yet recruiting

A Clinical Trial of XZP-6019 Tablets in Healthy Subjects

Non-alcoholic Fatty Liver Disease

China
Xuanzhu Biopharmaceutical Co., Ltd.

Not yet recruiting

Food Effect and Mass Balance Study of XZP-3621 Tablets

Healthy

China
Xuanzhu Biopharmaceutical Co., Ltd.

Recruiting

Effect of Food on the Pharmacokinetics of XZP-3287 in Healthy Subjects

Healthy

China
Beijing Kanova Biopharmaceutical Co., LTD

Active, not recruiting

Phase I of XKH001Injection in Healthy Adults

Healthy Adults

China
Beijing Kanova Biopharmaceutical Co., LTD

Not yet recruiting

XKH001 Injection in Healthy Subjects

Asthma
Binhui Biopharmaceutical Co., Ltd.

Not yet recruiting

OH2 Administered by Intratumoral Injection

Solid Tumor
Binhui Biopharmaceutical Co., Ltd.

Recruiting

OH2 Oncolytic Viral Therapy Via Transcatheter Intraarterial Infusion in Patients With Advanced Liver Cancer

Advanced Liver Cancer

China
Binhui Biopharmaceutical Co., Ltd.

Recruiting

First-line Maintenance of OH2 Injection for Advanced Colorectal Cancer

Advanced Colorectal Carcinoma

China
Binhui Biopharmaceutical Co., Ltd.

Recruiting

OH2 Injection in Solid Tumors

Melanoma | Solid Tumor

China
Binhui Biopharmaceutical Co., Ltd.

Recruiting

OH2 Oncolytic Viral Therapy in Solid Tumors

Solid Tumor | Gastrointestinal Cancer

China
Binhui Biopharmaceutical Co., Ltd.

Recruiting

OH2 Injection in Melanoma

Melanoma

China
Binhui Biopharmaceutical Co., Ltd.

Recruiting

Clinical Trial of Safety and Immunogenicity of Recombinant SARS-CoV-2 S-Trimer Vaccine (CHO Cells) as Booster Vaccination in Populations Aged 18 to 59 Years

COVID-19

China
Binhui Biopharmaceutical Co., Ltd.

Recruiting

OH2 Oncolytic Viral Therapy in Non-Muscle-Invasive Bladder Cancer

Non-muscle-invasive Bladder Cancer

China
Binhui Biopharmaceutical Co., Ltd.

Recruiting

OH2 Injection in Combination With HX008 for Melanoma.

Melanoma

China
Hasten Biopharmaceutical Co., Ltd.

Recruiting

Efficacy and Safety of Mexartan Potassium Tablets (AZL-M) and Calcium Channel Blockers (CCB) in the Treatment of Adults With Essential Hypertension in Chinese Population: a National Multicenter, Prospective, Observational Study

Essential Hypertension

China
Binhui Biopharmaceutical Co., Ltd.

Recruiting

oHSV2-PD-L1/CD3-BsAb Administered Via Intramural Injection

Solid Tumor

United States
Binhui Biopharmaceutical Co., Ltd.

Recruiting

OH2 Oncolytic Viral Therapy in Advanced Bladder Cancer

Advanced Bladder Carcinoma

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Recruiting

A Phase 1/2 Study of Donafenib in Combination With KN046 in Advanced Gastrointestinal Tumors

Advanced Gastrointestinal Tumors

China
Tasly Biopharmaceuticals Co., Ltd.

Recruiting

A Trial to Evaluate the Safety Tolerability and Pharmacokinetics of B1344 by Subcutaneous Injection in Healthy Subjects

Nonalcoholic Steatohepatitis

United States
Caliway Biopharmaceuticals Co., Ltd.

Completed

A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1)

Subcutaneous Fat

Australia
Caliway Biopharmaceuticals Co., Ltd.

Completed

A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 2)

Subcutaneous Fat

United States, Australia
Tasly Biopharmaceuticals Co., Ltd.

Completed

A Trial in Recombinant Human Prourokinase to Treat Acute Pulmonary Embolism (ERUPTE)

Acute Pulmonary Embolism

China
Caliway Biopharmaceuticals Co., Ltd.

Completed

A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of CBL-514 Injection for Reducing Convexity or Fullness of Abdominal Subcutaneous Fat

Subcutaneous Fat

Australia
Caliway Biopharmaceuticals Co., Ltd.

Recruiting

A Phase 2b Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat.

Subcutaneous Fat

United States
Tasly Biopharmaceuticals Co., Ltd.

Recruiting

rhPro-UK in Acute Ischaemic Stroke Within 4.5 Hours of Stroke Onset Trial 2(PROST-2) (PROST-2)

Acute Ischemic Stroke

China
Caliway Biopharmaceuticals Co., Ltd.

Active, not recruiting

A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat

Subcutaneous Fat

United States
Caliway Biopharmaceuticals Co., Ltd.

Completed

A Study to Evaluate the Pharmacokinetic Profile of CBL-514 Injection in Healthy Volunteers

Subcutaneous Fat

United States
Caliway Biopharmaceuticals Co., Ltd.

Completed

A Phase 1 Study to Evaluate the Safety and Tolerability of CBL-514 Injection on Convexity or Fullness of Abdominal Subcutaneous Fat in Healthy Volunteers

Subcutaneous Fat

Australia
Tasly Biopharmaceuticals Co., Ltd.

Completed

Study of rhPro-UK in Patients With Acute Ischaemic Stroke in 4.5 Hours After Stroke Onset(PROST)

Acute Ischaemic Stroke

China
Tasly Biopharmaceuticals Co., Ltd.

Completed

Thrombolysis With rhPro-UK in 4.5-6 Hours After Acute Ischemic Stroke in a Double-blinded,Controlled Trial (PROUD)

Acute Ischaemic Stroke

China
Caliway Biopharmaceuticals Co., Ltd.

Not yet recruiting

A Study to Evaluate the Efficacy and Safety of CBL-514 Compared to Placebo in Participants With Dercum's Disease Lipomas

Dercum's Disease
Tasly Biopharmaceuticals Co., Ltd.

Not yet recruiting

A Study of B1962, a PD-L1/VEGF Bispecific Antibody Fusion Protein, for Advanced Solid Tumors

Neoplasms Malignant

China
Caliway Biopharmaceuticals Co., Ltd.

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 2)

Cellulite

United States

Clinical Trials Sponsored by Xuanzhu Biopharmaceutical Co., Ltd.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jamaica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations